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Background: Human APOBEC3H (A3H) belongs to the A3 family of host restriction factors, which are cytidine
deaminases that catalyze conversion of deoxycytidine to deoxyuridine in single-stranded DNA. A3 proteins contain
either one (A3A, A3C, A3H) or two (A3B, A3D, A3F, A3G) Zn-binding domains. A3H has seven haplotypes (I-VII)
that exhibit diverse biological phenotypes and geographical distribution in the human population. Its single
Zn-coordinating deaminase domain belongs to a phylogenetic cluster (Z3) that is different from the Z1- and
Z2-type domains in other human A3 proteins. A3H HapII, unlike A3A or A3C, has potent activity against HIV-1.
Here, we sought to identify the determinants of A3H HapII deaminase and antiviral activities, using site-directed
sequence- and structure-guided mutagenesis together with cell-based, biochemical, and HIV-1 infectivity assays.
Results: We have constructed a homology model of A3H HapII, which is similar to the known structures of other
A3 proteins. The model revealed a large cluster of basic residues (not present in A3A or A3C) that are likely to be
involved in nucleic acid binding. Indeed, RNase A pretreatment of 293T cell lysates expressing A3H was shown
to be required for detection of deaminase activity, indicating that interaction with cellular RNAs inhibits A3H
catalytic function. Similar observations have been made with A3G. Analysis of A3H deaminase substrate specificity
demonstrated that a 5′ T adjacent to the catalytic C is preferred. Changing the putative nucleic acid binding
residues identified by the model resulted in reduction or abrogation of enzymatic activity, while substituting
Z3-specific residues in A3H to the corresponding residues in other A3 proteins did not affect enzyme function.
As shown for A3G and A3F, some A3H mutants were defective in catalysis, but retained antiviral activity against
HIV-1vif (−) virions. Furthermore, endogenous reverse transcription assays demonstrated that the E56A catalytic
mutant inhibits HIV-1 DNA synthesis, although not as efficiently as wild type.
Conclusions: The molecular and biological activities of A3H are more similar to those of the double-domain
A3 proteins than to those of A3A or A3C. Importantly, A3H appears to use both deaminase-dependent
and -independent mechanisms to target reverse transcription and restrict HIV-1 replication.
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The human APOBEC3 (A3) family consists of seven cyti-
dine deaminases that catalyze the conversion of deoxycy-
tidine (dC) to deoxyuridine (dU) in single-stranded (ss)
DNA, thereby inducing G-to-A hypermutation in double-
stranded DNA [1-5]. A3 proteins play an important role* Correspondence: levinju@mail.nih.gov
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unless otherwise stated.in the innate immune defense system by inhibiting a
broad range of exogenous viruses such as human im-
munodeficiency virus type 1 (HIV-1) (reviewed in refs.
[6-13]), human T-lymphotropic virus type 1 (HTLV-1)
[14,15], and hepatitis B virus (HBV) [16,17] as well as
endogenous retrotransposons such as LINE-1 and Alu
elements (reviewed in refs. [7,18]). These proteins con-
tain either one (A3A, A3C, and A3H) or two (A3B,
A3D (formerly known as A3D/E), A3F, and A3G) Zn-
binding domains with the conserved motif HX1EX23-24
CX2-4C (X is any amino acid) [19] (reviewed in refs.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Zn ion, while the glutamic acid residue is thought to
act as a proton shuttle during catalysis [6,22]. Based on
phylogenetic analysis, the Zn-binding domains were
further classified into the following groups: Z1 (A3A
and C-terminal domains (CTD) of A3B and A3G), Z2
(A3C, N-terminal domains (NTD) of A3B and A3G,
and both NTD and CTD of A3D and A3F), and Z3
(A3H) [23,24].
A3H is the most divergent member of the A3 family
and has a single Zn-binding domain that belongs to
the unique Z3 group [24,25]. The A3H message under-
goes alternative splicing to generate variants containing
distinct C-terminal regions [26,27]. Furthermore, unlike
other A3 genes, A3H is present in the human popula-
tion as different haplotypes containing functional poly-
morphisms. At present, seven haplotypes of A3H (Hap
I-VII) have been identified that differ in their antiviral
activities: only Hap II, Hap V, and Hap VII are stably
expressed and are able to restrict Vif-deficient HIV-1
[26-29]. Interestingly, the distribution of A3H haplotypes
in the human population is correlated with geographical
location [26,29]. For example, a higher frequency of HapII
is present in Africa, compared to Europe and Asia, pos-
sibly due to a greater selection pressure against pathogens
endogenous to that region [26].
HIV-1 Vif, which counteracts antiviral activity by pro-
moting proteasomal degradation of A3C, A3D, A3F, and
A3G, exhibits different degrees of potency against the
individual A3H haplotypes [12,29-32]. In cell-based as-
says, the sensitivity of antiviral A3H HapII towards Vif
was shown to be dependent upon the Vif subtype [33,34]
and a remarkable study involving recently infected
HIV-1 patients revealed adaptive changes in viral Vif
sequences that were attributed to the presence of the
different antiviral A3H haplotypes [32]. These observa-
tions provide strong evidence for a significant role of
A3H as an antiviral defense protein.
A3 proteins deaminate dC residues in a sequence-
specific manner. For example, A3A exhibits a greater
preference for the dC in the center of a TCA target
[35-42], while A3G specifically deaminates the dC in a
CCC motif [21,43-45]. Evaluation of the structural basis
of the sequence specificity suggested that it is deter-
mined by the architecture of the active site and sur-
rounding amino acids, in particular, residues in loop 7
[41-46] (reviewed in refs. [21,47]). Although, A3H is
known to deaminate dC in TC motifs of HIV-1 minus-
strand DNA [27,48], a detailed investigation of the nu-
cleotide context immediately 5′ and 3′ of the dC on
sequence-specific deamination has not been reported.
In addition, the amino acid residues that are important
for A3H deaminase activity and the role of structure in
dictating biological function have not been investigated.In the present study, we focus on the biochemical and
structural determinants of A3H HapII (to be referred to
as “A3H”) deaminase and antiviral activities, using site-
directed and structure-guided mutagenesis. We have
constructed a homology model of A3H and find that the
A3H structure, as expected, is similar to the known
structures of A3A [41], A3C [49], A3G-CTD [43,50-53],
and A3F-CTD [54,55], with differences mainly in flexible
loop regions. Our model resembles the ones generated
by (i) MODELLER [56], based on the A2 and A3G-CTD
structures [57], and (ii) the automated structure-homology-
modeling server, SWISS-MODEL, using the A2 structure
[13], although details may be different. Interestingly, our
model also reveals a large cluster of basic residues, which
is not present in other A3 deaminase-active domains, and
is consistent with the observation that deaminase activity
in cell-free extracts is detected only after removal of RNA
by treatment with RNase A. In addition, we have evalu-
ated the deaminase and antiviral activities of a series of
A3H mutants. Although these activities can be correlated
in most cases, a significant number of mutants lacking en-
zymatic activity are still able to inhibit HIV-1 replication,
albeit at a lower efficiency than wild type (WT). This
result raises the possibility that A3H restricts HIV-1 by
catalytic-dependent and -independent mechanisms. In-
deed, assays of endogenous reverse transcription (ERT)
support this hypothesis. Taken together, our findings
provide new insights into the role of A3H as a naturally
occurring human restriction factor and should contrib-
ute to continuing efforts to combat HIV infection in
the African human population.
Results
Sequence- and structure-based design of A3H mutants
In this work, we set out to investigate the determinants
of A3H cytidine deaminase and antiviral activities, using
a mutagenic approach. Given A3H's unique Z3-type Zn-
binding domain [24], we initially carried out a sequence
comparison of the Z3 domain of A3H with the Z1 and
Z2 domains of other A3 proteins to identify conserved
and distinct regions in A3H (Additional file 1: Figure S1).
Sequence identities range from 28-43% and the Z3 do-
main shares the greatest identity with the Z2 domains of
A3C and A3F-CTD and the least with A3D-NTD. The se-
quence alignment also identified four residues unique to
the Z3 domain: T81, L102, S109, and V135, which are re-
placed by S, V, A, and I in other Z domains.
A more extensive sequence alignment was performed by
comparing the residues in the complete A3H protein with
the sequences of A3 proteins whose three-dimensional
structures have been solved at high resolution, i.e.,
A3A [41], A3C [49], A3F-CTD [54,55] and A3G-CTD
[43,50-53] (Figure 1). The overall sequence identity bet-
ween A3H and each of these proteins is very similar and
Figure 1 Sequence alignment of A3H HapII (residues 1 to 183) and four A3 deaminase-active proteins whose structures have been
solved: A3A (1 to 199) [41], A3C (1 to 190) [49], A3F-CTD (185–373) [54,55], and A3G-CTD (191–384) [53] (also see refs. [43,50-52]).
The A3H residues mutated in this study are highlighted with green asterisks and the active site residues are highlighted in blue. The region inside
the square brackets represents the Z domain sequences for all of the proteins. The amino acids that comprise A3H loop 7 are also shown. The
sequence alignment was generated using Lasergene software (DNASTAR, Inc., Madison, WI, USA).
Mitra et al. Retrovirology  (2015) 12:3 Page 3 of 15ranges from 35 to 38% (Table 1). The Z domains (bracketed)
include the loop 7 residues, a region that is involved in
deaminase substrate specificity [41-46] (reviewed in
[21,47]). Interestingly, loop 7 sequences for different A3
proteins display alternative arrangements of polar and
non-polar residues. For example, A3H contains a stretch
of aromatic residues (YYHW, 112–115), while in A3G-
CTD, the corresponding residues are polar (YDDQ, 315–
318). In addition, a unique stretch of residues was noted
outside the Z domains, namely 154–157 (PLSF), which is
absent in the other A3 proteins.
To probe the role of A3H residues in enzymatic ac-
tivity in relation to their location in the structure, we
constructed a homology model based on the X-ray struc-
ture of A3G-CTD [53] (Figure 2A). Comparison of our
A3H model with A3G-CTD (PDB: 3IR2) [53], A3A (PDB:
2 M65) [41], A3C (PDB: 3 VOW) [49], and A3F-CTD
(PDB: 4IOU) [54] showed that the A3H model is similar
to the other A3 structures, which have r.m.s.d. values ran-
ging from 3.1 to 3.5 Å. The major differences between theTable 1 Sequence comparison of A3H with other
deaminase-active A3 proteins and theoretical isoelectric
points (pI)
Zinc-binding
domain (Z)
type
% Sequence
identity to
A3Ha
Theoretical pIb
A3A (1–199) Z1 36 6.3
A3C (1–190) Z2 38 7.5
A3F-CD2 (185–373) Z2 36 5.0
A3G-CD2 (191–384) Z1 35 6.2
A3H HapII (1–183) Z3 100 8.9
aSequence identity analysis was performed using Lasergene software
(DNASTAR, Inc.).
bThe theoretical pI values were calculated using the Protparam online
web-based program (http://web.expasy.org/compute_pi/).various A3 structures occur in the loops, as suggested pre-
viously [41] (Additional file 2: Figure S2).
Comparisons of the electrostatic surface features of
A3H (Figure 2B, Additional file 3: Figure S3) and other
A3 proteins (A3G-CTD, A3A, A3C, and A3F-CTD)
(Additional file 3: Figure S3) reveal a striking difference
in the clustering of basic residues (blue regions), con-
sistent with the fact that A3H is highly basic (theoret-
ical pI, 8.9) compared to the other single-domain A3
proteins A3A (pI, 6.3) and A3C (pI, 7.5) (Table 1). In-
deed, the basic character of A3H is more similar to the
positively charged N-terminal domains (NTDs) of the
double-domain proteins, A3F (residues 1–180; pI, 8.6)
and A3G (residues 1–185; pI, 9.4). The NTDs of A3F
and A3G play an important role in binding viral RNA
that is packaged; however, they are enzymatically in-
active [58-61]. Since A3H is a single-domain protein, it
is likely that the basic residues serve a dual function, i.e.,
binding both viral and/or cellular RNA as well as interact-
ing with the ssDNA substrate for deamination.
RNA inhibits the deaminase activity of A3H
Deaminase activity of A3H variants was tested in 293T
cell lysates using a TTCA-containing 40-nt oligonucleo-
tide as described in Methods; protein expression was
monitored by Western blot analysis, using an A3H-
specific antibody probe (Figure 3A). We selected the
TTCA motif, since analysis of HIV-1 viral DNA showed
that the dC residue in TC motifs was preferentially de-
aminated by A3H [27,32,48,62]. Surprisingly, we observed
only trace amounts of deaminase activity in (WT) A3H
cell lysates (Figure 3B and C). However, activity was
clearly detectable after treating these lysates with RNase
A, while no effect was seen with cells transfected with the
empty vector control. These results suggest that A3H is
Figure 2 A3H model structure. (A) Ribbon representation of the A3H model showing the positions of residues mutated in this study in green.
The Zn ion is colored in brown. (B) Electrostatic map of the A3H model depicting regions with positive (blue) and negative (red) electrostatic
potentials. Basic residues are shown in white.
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action with RNA inhibits A3H deaminase activity, pre-
sumably in a competitive manner. Interestingly, a similar
inhibitory effect on enzyme function was also observed
with A3G [7,63].
Deaminase target specificity of A3H
Until now, detailed analysis of A3H deaminase specificity
has not been reported. We therefore performed deaminase
assays using oligonucleotides containing different motifs:
TTCA, TTCT, TTCG, TGCA, and ACCCA, where either
a purine (G) or a pyrimidine (T or C) is present at the pos-
ition immediately 5’ of the target dC residue. As shown in
Figure 3D, the presence of a 5′ T (e.g., TTCA, TTCT, and
TTCG) yielded the highest amounts of deamination pro-
duct (~90% substrate conversion with 5 μg of total pro-
tein after incubation for 1 h at 37°C), while a 5′ G, as in
TGCA, was poorly tolerated (~17%). The rank order of
deamination efficiency of the substrates is: TTCA ~
TTCT ~ TTCG > ACCCA > TGCA. These data suggest a
less stringent requirement for the 3′ position, where ei-
ther a purine or a pyrimidine is tolerated, since similar
levels of deamination product were formed with sub-
strates containing TTCA, TTCT, and TTCG motifs.
(Note that some difference in the deamination efficiency of
substrates with TTCA, TTCT, and TTCG motifs might
occur if less than 1 μg of lysate were added to the reaction.)
Identification of A3H residues important for deaminase
activity
The sequence-structure analysis (Figures 1 and 2) provided
a rationale for mutagenesis of A3H residues that couldpotentially play a role in catalytic activity. Deaminase and
HIV-1 infectivity assays of WTand mutant constructs were
performed in parallel to evaluate enzymatic (Figure 4) and
antiviral (Figure 5) activities. The data in Figure 4A and D
are arranged according to residue position along the poly-
peptide chain from the N- to C-terminus. As expected, the
active site mutant E56A (negative control) did not display
any deaminase activity (Figure 4B).
In our initial screen, we focused on residues that are
Z3-specific (Additional file 1: Figure S1), in order to
probe whether these residues were selected throughout
evolution to ensure A3H enzymatic activity. We chose
two examples from this group, T81 and V135, which cor-
respond to S and I, respectively, in Z1 and Z2 Zn-binding
domains (Figure 1). Mutants with these Z1-Z2 substitu-
tions were expressed at levels comparable to or higher
than WT (Figure 4A and D). Interestingly, changing T81
to S did not reduce deaminase activity, whereas the T81 to
A mutation completely abolished activity (Figure 4B).
Note that the mutant protein T81A was expressed at
levels comparable to WT (Figure 4A). Since both threo-
nine and serine possess a hydroxyl group, while alanine
does not, this may suggest that the side chain of T81 is in-
volved in a polar interaction. Changing the analogous resi-
due S97 in A3A (Z1 type) to T did not affect deaminase
activity (Figure 4B), consistent with retention of the im-
portant hydroxyl group. Similarly, mutating V135 to I also
represents a conservative change and not surprisingly,
there was no effect on enzymatic activity (Figure 4E).
In contrast, deletion of the unique stretch of amino
acids, PLSF (aa 154–157), which contains three bulky hy-
drophobic residues, proline, leucine, and phenylalanine,
Figure 3 A3H deaminase activity dependence on RNase A treatment of extracts and substrate specificity. (A) Western blot analysis
showing the WT A3H protein levels in 293T cells. Transfection of the empty vector (no A3H) served as a negative control and showed that 293T
cells do not contain detectable levels of endogenous A3H. The tubulin loading control is also shown. (B) Representative gel illustrating assay of
WT A3H deaminase activity in a cell extract using a 40-nt TTCA-containing oligonucleotide substrate. The oligonucleotide was incubated with
increasing amounts of A3H extract in the presence and absence of RNase A. The positions of the substrate (40 nt) and the deamination product
are indicated by arrows to the right of the gel. Lane 1, empty vector control; lanes 2 and 6, lanes 3 and 7, lanes 4 and 8, and lanes 5 and 9
represent reactions containing 1 μg, 2 μg, 3 μg, and 5 μg of total protein, respectively. (C) The percent (%) deamination product was calculated as
described in Methods and was plotted against the amounts of total protein. (D) Deaminase assay using WT A3H extract and 40-nt oligonucelotides
containing the following deaminase motifs: TTCA, TTCT, TTCG, TGCA, and ACCCA. The data were analyzed and plotted as described in (C).
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This suggests that a major conformational change was
introduced by the deletion, causing an overall structural
defect. In turn, this would lead to destabilization of the
protein, which could explain the low protein expres-
sion level of this mutant (Figure 4D) and inability to bepackaged efficiently (see below) (Figure 5A). Changing
another unique A3H residue, P25 to R, abrogated A3H
deaminase activity (Figure 4B), although its expression
level was normal (Figure 4A).
Basic residues in A3 proteins are often involved in spe-
cific and non-specific nucleic acid interactions [21,47,64].
Figure 4 Deaminase activities of A3H WT and mutants. (A) and (D) Western blot analysis showing the amounts of A3H WT and mutants and
A3A S97T in 293T cells. (B, C, E, F) Deaminase assays using 293T cell extracts expressing A3H WT and mutants and A3A S97T. The deaminase
assays were performed as described in Methods.
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activity (Figure 4C and F) and to determine whether the
location of these residues in the A3H model structure is
related to their function, we focused on residues in the
“basic patch” (Figure 2B): R17, R18, R20, R21, R110, K168,
and R171. Note that R18, R20, and R21 are not present in
other A3 proteins (Figure 1). We constructed a single mu-
tant with an R→D change (R110D) as well as double mu-
tants R17D/R18D, R20D/R21D, and K168A/R171A. With
the exception of R17D/R18D and R110D, the mutant pro-
teins were efficiently expressed (Figure 4A and D), but al-
most all lacked deaminase activity (Figure 4C, 4E, and F),
even at high amounts of total protein. Two mutants, del
(20–22) (Figure 4C) and K168A/R171A (Figure 4E), dis-
played greatly reduced, but measurable activity (~15%
and ~11% product, respectively, at 5 μg total protein).
These results suggest that positive charges are necessary
for binding of A3H to the ssDNA substrates and that
the introduction of a single negative charge in the basicpatch disrupts the favorable charge-charge interaction.
The change to the non-polar alanine or deletion of resi-
dues 20–22, which are present only in A3H as a unique
insertion, is less detrimental. Taking all of the above
data together, it appears likely that these basic residues
form part of the A3H nucleic acid binding interface.
Another region of interest, loop 7 (Figure 1), which in other
A3 proteins has been shown to be important for substrate
binding and recognition [41-46] (reviewed in refs. [21,47])
was also subjected to mutagenesis. Several of the mutant pro-
teins e.g., W115A, W115F, del(115), and Y113D/H114D/
W115Q (YHW/DDQ) were expressed at low levels compared
to WTA3H (Figure 4D), possibly resulting from reduced pro-
tein stability due to removal of the large tryptophan side
chain. Changing residues Y112, Y113, and H114, e.g., Y112A,
Y113D/H114D (Figure 4F), and YHW/DDQ, which intro-
duces polar residues from the A3G-CTD loop 7 (Figure 4E),
led to the complete loss of deaminase activity. A similar result
was obtained when W115 was deleted (del115) or changed to
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Figure 5 Antiviral activities of A3H WT and mutants. (A) Western blot analysis showing the amounts of A3H WT and mutants in HIV-1vif (−)
virions and 293T cells. 293T cells were transfected with HIV-1vif (−) and A3H WT or mutant plasmids at a 1:1 ratio (1 μg each for determination of
expression in cell extracts and 8 μg each for determination of A3H in viral lysates). Cell extracts (10 μg of total protein) as well as viral lysates
(8 μl of viral pellet resuspended in 200 μl of loading buffer) were subjected to Western blot analysis. Viral lysates were probed with antibodies to
the N-terminal FLAG tag of A3H and HIV-1 CA; cell extracts were probed with antibodies to the N-terminal FLAG tag of A3H, HIV-1 Gag (Pr55gag),
and tubulin. Controls: Left side, EMPTY refers to HIV-1vif (−) and empty vector (pTR600); Right side, EMPTY refers to empty vector alone; WT, refers
to A3H plasmid DNA alone. (B-D) Antiviral activity was determined as described in Methods. The gray and black bars respresent transfection with
0.1 μg or 1 μg of the indicated A3H plasmid, respectively.
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phan to another aromatic residue, phenylalanine (W115F)
(Figure 4F), led to only partial loss of deaminase activity,
suggesting that these aromatic residues could be involved
in base stacking interactions with the nucleic acids. Finally,
we tested the deaminase activity of W115A, del115,
Y113D/H114D, YHW/DDQ, and R110D at 10 μg total pro-
tein, but again, no activity was observed (data not shown).
Collectively, these results suggest that the residues in A3H
loop 7 are also likely to participate in specific interactions
with nucleic acids.Role of A3H residues in A3H antiviral activity
Inhibition of HIV-1vif (−) replication by A3F and A3G is me-
diated by both deaminase-dependent and -independent mech-
anisms [20,61,65-79]. In an early study, it was concluded that
A3H antiviral activity is deaminase-independent [80], but other
reports indicated that this activity is dependent on catalysis
[25,27]. It was therefore of interest to evaluate whether the
presence or absence of deaminase activity (Figure 4) could be
correlated with A3H antiviral activity (Figure 5) in our system.
To determine whether the inability of certain mu-
tants to restrict HIV-1 replication was due to a defect
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(Figure 5A). Virions were probed for capsid protein (CA)
as well as for A3H. For comparison, expression levels of
A3H and tubulin in cells were also measured and the data
were similar to the results in Figure 4A and D. Interest-
ingly, several mutants that were expressed poorly in cells,
packaged little or no A3H in virions (Figure 5A). These
mutants include: R17D/R18D, Y113D/H114D, W115A,
and del(154–157). Although W115F exhibited lower levels
of protein than WT (Figures 4D and Figure 5A), a signifi-
cant amount of A3H was encapsulated (Figure 5A).
Single-cycle infectivity assays of virions produced in
cells expressing WT and mutant A3H proteins were per-
formed using two different amounts of A3H plasmid
(0.1 μg and 1 μg). Under conditions where the 0.1 μg
dose was used, the antiviral activities of the mutants
could be divided into three groups: (1) mutants that
showed little or no deaminase or antiviral activities (i.e.,
having values similar to the empty vector control), such
as R17D/R18D, R20D/R21D, del(20–22) (low level of de-
aminase activity), Y113D/H114D, W115A, W115F (re-
duced level of deaminase activity), del(115), and del
(154–157) (Figure 5B); (2) mutants with WT levels of
deaminase activity and appreciable antiviral activity, al-
beit lower than that of WT, such as T81S and V135I
(Figure 5C); and (3) mutants completely lacking (P25R,
E56A, T81A, Y112A) or having reduced levels (K168A/
R171A) of deaminase activity that retain antiviral activity
(Figure 5D).
The results obtained with mutants in groups 1 and 2
are consistent with deaminase-dependent antiviral activity,
since group 1 mutants have neither activity and group 2
mutants have both. With the exception of R20D/R21D,
del (20–22), and W115F, all of the group 1 mutants that
were analyzed by Western blot exhibited packaging de-
fects (see above), which would account for their lack of
virion-associated deaminase and anti-HIV activities. Inter-
estingly, the results with group 3 mutants were discordant
and suggest that A3H may also utilize a deaminase-
independent mechanism for HIV-1 restriction. Note that
the levels of antiviral activity for these deaminase-negative
mutants were still lower than WT values (0.1 μg condi-
tion), suggesting that deaminase activity is indeed required
for maximal activity.
The antiviral activities of WT and a majority of the
mutants increased upon increasing the transfected plas-
mid amount to 1 μg. Surprisingly, the antiviral activities
of T81S and Y112A were similar to WT levels under this
condition. The behavior of Y112A in our study differed
from that of A3H Hap VII Y112A, which although ex-
pressed efficiently in cells, was poorly packaged and
exhibited a very low level of anti-HIV-1 activity [29].
The explanation for this difference is not clear. We also
performed a side-by-side comparison of the activitiesof the deaminase-negative catalytic mutants of A3G
(E259Q) and A3H (E56A) as well as the respective WTs
(Additional file 4: Figure S4) and found that both A3H
and A3G WT and mutant samples displayed dose-
dependent inhibition of HIV-1 infectivity. This suggests
that A3G and A3H utilize a common mechanism for
antiviral activity.
Mechanism of A3H antiviral activity
A3G and A3F deaminase-independent anti-viral ac-
tivity targets nascent DNA synthesis during reverse
transcription [20,68-79]. To determine whether A3H
deaminase-independent inhibition of HIV-1 infectivity
is also associated with a reduction in viral DNA syn-
thesis, we performed ERT assays using WT A3H and
the active site mutant E56A.
In our assays, HIV-1vif (−) and A3H plasmids were
transfected at two different ratios: 10:1 or 3:1, respectively
(see Methods). Synthesis of R-U5 DNA (minus-strand
strong-stop DNA) and R-5’UTR DNA (plus-strand DNA
synthesized after plus-strand transfer) was measured over
a 4-h time interval (Figure 6A and B). With WT A3H
using the 10:1 condition, the levels of R-U5 were de-
creased to about 40% of the minus A3H control (100%) at
2 h (Figure 6A). The levels were drastically reduced for
WT (3:1 condition) (~15% at 2 h) and the time course
showed no appreciable change in level over the 4-h win-
dow. The E56A mutant, which lacks deaminase activity,
was also capable of reducing the R-U5 levels to about 60%
at 2 h (10:1 condition). At the higher dose (3:1 condition),
R-U5 levels were further reduced relative to the control
(~25% at 2 h), but the inhibition did not saturate even
after 4 h, indicating partial inhibition. Similar trends for
the WT and E56A mutant were also observed when
synthesis of R-5′UTR (plus-strand synthesis) was moni-
tored (Figure 6B). These results demonstrate that A3H
deaminase-independent HIV-1 restriction involves in-
hibition of viral DNA synthesis.
Discussion
In this work, we use sequence- and structure-guided
mutagenesis to provide a detailed analysis of A3H deam-
inase activity and to correlate enzymatic function with
antiviral activity. In addition, we identify the A3H struc-
tural elements associated with these activities. We also
show that A3H deaminase activity in cell extracts is sup-
pressed by binding to cellular RNAs (Figure 3), consist-
ent with an earlier report indicating that A3H interacts
strongly with 7SL, Y1, Y3, and Y4 RNAs in 293T cells
[57]. Interestingly, extensive mutagenesis studies dem-
onstrate that the determinants of deaminase and anti-
viral activities are not necessarily the same, as a number
of deaminase-negative mutants retain antiviral activity
(Figures 4 and 5). Thus, A3H appears to inhibit HIV-1
Figure 6 ERT assays of virions produced following transfection of 293T cells with HIV-1vif (−) and WT A3H or the E56A active site
mutant. (A and B) Kinetics of DNA synthesis in ERT assays measuring the levels of R-U5 (A) and R-5′UTR (B). The assays were performed as
described in Methods. Note that synthesis of R-U5 DNA was more efficient than synthesis of R-5’UTR DNA in the presence of WT A3H under both
the 10:1 and 3:1 conditions: the time required for 50% inhibition was 2 h for R-U5 and 3 h for R-5’UTR over the time course of the analysis.
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mechanisms.
To assess the molecular and structural properties of
A3H Hap II, we generated a homology model based on
the crystal structure of A3G-CTD (PDB: 3IR2) [53].
The electrostatic surface potential of the A3H model
identified a “large basic patch” (Figure 2B, blue region),
containing a cluster of basic residues that could be po-
tentially involved in specific binding to ssDNA sub-
strates as well as binding to cellular RNAs. While this
manuscript was under review, a paper by Shandilya et al.
[81] appeared, presenting homology models of the indi-
vidual domains of several A3 proteins, including A3H.
An electrostatic map of this A3H model also revealed alarge basic patch. In fact, comparison of the two structures
did not show any significant structural differences.
The basic nature of A3H is important and impacts
catalytic function. Thus, deaminase activity is strongly
inhibited upon mutating a subset of the basic residues
(R17, R18, R20, R21, Figure 4C; R110, Figure 4F; K168,
R171, Figure 4E), suggesting reduced binding to the 40-
nt nucleic acid substrate. Arginine mutants that were
tested also lacked antiviral activity (Figure 5B). However,
the basic residues may not all function in the same man-
ner, since the double mutant K168A/R171A retained
some deaminase (Figure 4E) as well as restriction activity
(Figure 5D). Interestingly, the region corresponding to
R17 to P22 in A3H (containing four basic residues) is
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other A3 domains (Figure 1). In A3A, this region is
completely missing, while in A3C, A3G-CTD, and A3F-
CTD, there is a loss of four (A3C, A3G-CTD) or two
(A3F-CTD) basic residues. Deletion of A3H residues
R20, R21, and P22 (the del(20–22) mutant) results in
significant loss, but not complete abolition of deaminase
activity (Figure 4C), possibly due to perturbation of the
local structure in the mutant protein. Although this mu-
tant is efficiently packaged into virions (Figure 5A), it
cannot restrict HIV-1 (Figure 5B).
Residues in A3H that are unique to its Z3 domain e.g.,
T81 and V135 are replaced in other active deaminase
domains by S and I respectively, which are chemically
similar (Figure 1 and Additional file 1: Figure S1). This
implies similarity in function and is consistent with our
finding that the A3H mutants T81S and V135I, retain
enzymatic (Figure 4B and E, respectively) as well as re-
striction activity (Figure 5C). However, the T81A mutant
in which the hydroxyl group common to T and S, is re-
moved, has only background levels of deaminase activity
(Figure 4B). This suggests an important structural role
for the hydroxyl group at this position, possibly partici-
pation in hydrogen bonding interactions with a nearby
side chain. In fact, the Oγ atom of S284, the correspond-
ing residue in A3G, is within hydrogen bonding distance
to the Y219 HN backbone atom and is also observed in
other A3 proteins [41,43,49,54]. It is interesting that des-
pite lacking enzymatic activity, the T81A mutant exhibits
significant antiviral activity (Figure 5D).
Although the loop 7 element of A3 proteins plays an
essential role in determining deaminase specificity, each
protein possesses a unique sequence (Figure 1) and is
affected differently when subjected to mutation. For
example, as indicated by modeling the A3A/ssDNA
complex, the A3A loop 7 cluster of residues (127-ARIY-
DYDPL-135) interacts with the T (D133) and A (D131,
Y132, and D133) nucleotides in the TCA motif, while
D131 makes contacts with the central C [41]. Substitu-
tions in all four cluster residues lead to complete loss of
A3A deaminase activity [42]. In the case of the A3G-
CTD loop 7 (313-RIYDDQGR-320), mutation of the
only aromatic residue, Y315, negatively impacts deami-
nase activity [43]. Additionally, changing both D316 and
D317 to R [43] or replacing D317 with the correspon-
ding A3A residue (Y132) [46] results in altered deami-
nase substrate specificity, as manifested by preferential
deamination of the central C in the motif CCC ins-
tead of the 3′ C (CCC). Exchanging the A3H loop 7
(109-SRLYYHWCK-118) cluster residues YHW with
the corresponding A3G-CTD residues, DDQ (YYHW→
YDDQ), abrogates deamination activity (Figure 4E). This
could reflect a change in substrate specificity or in the de-
tails of the nucleic acid binding mode due to a proteinconformational change. Interestingly, a similar switch in
sequence in the case of A3A (YDYD→YDDD) also re-
duces activity to background levels [42].
The importance of the A3H W115 residue in loop 7 is
underscored by our finding that mutation of W115 to A
results in low cellular protein levels (Figures 4D and
5A), blocks packaging into virions (Figure 5A), and elim-
inates deaminase (Figure 4F) and antiviral (Figure 5B)
activities. Wang et al. [29] were unable to detect expres-
sion of (Hap VII) W115A in 293T cells, while Zhen et al.
[57] reported that (Hap II) W115A is present at low
levels in cell lysates. However, even when expression is
equivalent to that of WT (by transfecting cells with a
high amount of the Hap II mutant plasmid), W115A is
barely detectable in viral lysates, does not restrict HIV-1,
and binds cellular RNAs with greatly reduced efficiency
[57]. Collectively, these results lend further support to
the conclusion that the identity of loop 7 residues is crit-
ical for enzyme function.
Surprisingly, although A3H is highly basic and has
only one domain, it more closely resembles the double-
domain proteins A3D, A3F, and A3G than the single-
domain A3A and A3C proteins with respect to several
important biological properties. For example, like A3D,
A3F, and A3G [53,64,82-92], A3H associates in solution
in the absence of nucleic acid [93] and forms multimers
and high molecular weight ribonucleoprotein complexes
in cells [92,94]. In addition, it restricts the infectivity of
HIV-1vif (−) virions (Figure 5) [26,27,62,80,94]. The anti-
HIV-1 activity of A3 proteins A3D, A3F, A3G, and A3H
involves (i) packaging of the proteins into the cores of
nascent virions in the producer cell [28,36,95,96]; and
(ii) inhibition of viral replication in the target cell
(reviewed in ref. [9]). These parameters are linked to
subcellular localization, which varies among the A3
proteins. However, in this case too, just as A3D, A3F,
and A3G are located in the cytoplasm [82-84,86,92,97-99],
A3H haplotypes that have antiviral activity (e.g., Hap II)
are predominantly cytoplasmic [28,100].
The packaging of antiviral A3 proteins inside the HIV-1
core allows them to interact directly with viral nucleic
acids (genomic RNA and nascent DNA synthesized dur-
ing reverse transcription) in the presence of nucleocapsid
protein and reverse transcriptase (RT). Here we show
that A3H inhibits viral infectivity by both deaminase-
dependent and -independent mechanisms (Figure 5),
although it is likely that deaminase-dependent activity
is dominant (compare data for WT and the catalytic
mutant E56A in Figure 5D, Figure 6, Additional file 4:
Figure S4). For A3G, we have proposed a “roadblock”
mechanism that is based on its tight nucleic acid bind-
ing [61,101] and that is independent of catalytic activity
[69,74]. We reasoned that since A3G displays slow on-
off binding kinetics [69,79], RT is unable to traverse the
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catalyzed polymerization is blocked. Recent single mol-
ecule stretching studies in support of this mechanism
showed that A3G can transform from a fast enzyme (re-
quired for deamination) to a slow enzyme (causing a road-
block) during the course of protein oligomerization [79].
The highly basic character of the A3H protein (Figure 2B,
Table 1) (like the NTDs of A3D, A3F, and A3G) strongly
suggests that it also binds tightly to viral RNA and DNA,
in agreement with studies of A3H binding to cellular RNA
[57]. Moreover, the observed reduction in minus- and
plus-strand DNA synthesis by RT, even in the absence of
deaminase activity (Figure 6) and the fact that A3H can
multimerize [92,93] suggest that a roadblock mechanism
might also be relevant to A3H deaminase-independent
HIV-1 restriction (Figure 6). Interestingly, although A3H
mediates hypermutation of HIV-1 [27,48,62] and HBV [17]
DNA, the antiviral activity of A3H against HTLV-1 does
not involve editing [15].
In summary, A3H as well as A3D, A3F, and A3G con-
stitute a group of A3 proteins used by the human innate
immune system in its arsenal against HIV-1. The select-
ive pressure to maintain expression of antiviral haplo-
types of A3H in certain populations warrants greater
understanding of this protein in terms of its molecular
properties. Here, we present such an analysis and correl-
ate enzyme function and antiviral activity. Although
A3H is a single-domain protein and the most divergent
member of the A3 family, we show that it utilizes strat-
egies similar to those used by other antiviral double-
domain A3 proteins (A3D, A3F, and A3G) to counteract
HIV-1 infectivity. Knowledge of A3H structure-function
relationships should be invaluable for the design of
drugs to modulate A3H deaminase activity and augment
its anti-HIV effect. Furthermore, since A3H is a single-
domain protein and contains a unique Z3 domain, it
may present a more specific target than the double-
domain antiviral A3 proteins. Thus, taken together, A3H
clearly provides a molecular paradigm to explore the
antiviral response of A3 proteins to retroviral pathogens.
Conclusions
Based on a homology model of A3H Hap II and the results
of extensive mutagenesis, we have identified structural ele-
ments and key residues associated with A3H deaminase
and anti-HIV-1 activities. In addition, we provide evidence
that A3H restriction of HIV-1 replication and inhibition
of reverse transcription occur by deaminase-dependent
and -independent mechanisms.
Methods
Materials
DNA oligonucleotides labeled with AlexaFluor 488® were
obtained from Integrated DNA Technologies (Coralville,IA). The concentration of each oligonucleotide was de-
termined by measuring its absorbance at 260 nm, using
the extinction coefficients provided by the manufacturer.
RNase A (endonuclease-free) was purchased from Qiagen
Inc. (Germantown, MD). Escherichia coli uracil DNA gly-
cosylase (UDG) was obtained from New England Biolabs
(Beverly, MA). Gel loading buffer and nuclease-free
water were purchased from Ambion® (Life Technologies,
Grand Island, NY). Anti-A3H sera (p3A3 or p1H6), anti-
HIV-1 CA sera (for ERT experiments), and TZM-bl cells
(from John C. Kappes, Xiaoyun Wu, and Tranzyme Inc.)
[102-104] were obtained from the AIDS Research and Ref-
erence Reagent Program (Division of AIDS, NIAID, NIH).
An anti-HIV-1 p24 monoclonal antibody was purchased
from ZeptoMetrix (Franklin, MA) and was used for detec-
tion of CA and Pr55gag in virions and cell lysates, respect-
ively (see Figure 5). A monoclonal antibody (Anti-FLAG
M2) against a FLAG tag was obtained from Sigma-
Aldrich (St. Louis, MO). Anti-tubulin antibody was pur-
chased from Abcam (Cambridge, MA).
Construction of the A3H HapII homology model
The initial A3H Hap II homology model was construc-
ted without a Zn atom and was based on the A3G-CTD
crystal structure (PDB: 3IR2) [53] by using MODELLER
version 9v8 [56] and the sequence alignment shown in
Figure 1. The Zn atom was subsequently added to the
structure at a position equivalent to that in the structure
of A3G-CTD. This was followed by energy minimization
where only the Zn ion and the H54, C85, C88 side-chains
were allowed to move. During the energy minimization,
the lengths of the coordination bonds were kept as fol-
lows: 1.90 Å for the bond between the Zn ion and the
H54 Nδ1 atom; and 2.25 Å for the bond between the Zn
ion and the C85 or C88 Sγ atom. The charge of individual
atoms and their radius parameters based on an amber
force field [105] were generated by the pdb2pqr program
[106]. Partial charges of atoms within the Zn coordination
site were manually adjusted to +1e for the Zn ion, −0.6e
for the Sγ atom and +0.1e for the Cβ atom of the cyste-
ines to account for the approximate redistribution of
the charges between the two reduced cysteines and Zn
ion through the coordination bonds. All structure and
electrostatic potential map figures were generated with
MOLMOL [107]. Sequence identity was determined with
DNAStar (http://www.dnastar.com/megalign_help/index.
html#!Documents/calculationofpercent.htm).
Construction of A3H mutants
pTR600 mammalian expression plasmids without an in-
sert [108] or containing the A3H HapII coding sequence
[27] were a generous gift from Viviana Simon (Mount
Sinai School of Medicine, New York, NY) and had either
no tag or an N-terminal Flag tag. A3H mutants were all
Mitra et al. Retrovirology  (2015) 12:3 Page 12 of 15constructed in the pTR600 A3H-Flag vector using the
QuikChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) or the Tagmaster
Site-Directed Mutagenesis Kit (GM Biosciences, Rockville,
MD). For primer design, the on-line QuikChange Primer
Design Program provided by the manufacturer or the de-
sign guidelines provided with the Tagmaster kit were used.
Large-scale plasmid preparations were obtained using the
HiSpeed Plasmid Maxi Prep kit (Qiagen, Inc.). The A3H
sequence in each plasmid was verified by DNA sequen-
cing performed by ACGT (Wheeling, IL).
Preparation of mammalian cell extracts
Propagation of 293T cells, transfection procedure, prep-
aration of cell extracts, and determination of protein
concentration were performed as detailed in Mitra et al.
[42]. The expression levels of A3H were estimated by
subjecting ~20 μg of total protein in the extract to Western
blot analysis using the Western Breeze chemiluminescent
Western blot kit (Life Technologies). The primary anti-
bodies used for this analysis were anti-A3H or anti-tubulin
(loading control).
Deaminase assay
Prior to performing the deaminase assay, the 293T cell
extract (20 μg) was treated with RNase A (Qiagen, final
concentration 1 μg/μl) in a 20-μl reaction volume and
incubated at 37°C for 15 min, unless indicated otherwise.
Details of the deaminase assays and polyacrylamide gel
analysis are described in Mitra et al. [42]. A list of oligo-
nucleotides used for the deaminase assays is given in
Additional file 5: Table S1. Throughout the text, the dC
residue that is deaminated is highlighted in bold (C). A
40-nt Alexa-Fluor 488-labeled ssDNA (JL913) containing
the TTCA deaminase motif was used as the substrate, un-
less specified otherwise. To calculate the percent deami-
nase product, the product signal intensity for each lane
was divided by total signal intensity and multiplied by 100.
The data presented represent the average of two determi-
nations from two independent transfections. Note that the
FLAG tag did not interfere with deaminase activity, as
untagged and tagged WT A3H showed similar levels of
activity (Figure 4C).
HIV-1 infectivity assay
To assay the effect of expressing A3H WT or mutant
proteins on HIV-1 infectivity, 293T cells were cotransfected
with 1.0 μg of pNL4–3vif (−), which was kindly provided by
Klaus Strebel (National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, MD) and
1.0 or 0.1 μg of the pTR600 A3H HapII plasmid (WT or
mutant) or pTR600 empty vector (control), using the
FuGENE HD transfection agent (Promega, Madison, WI)
as previously described [49]. Virus-containing supernatantswere collected 48 h after transfection and filtered. The
amount of CA protein (i.e., p24 antigen) in the supernatant
was determined by ELISA assay (ZeptoMetrix, Buffalo,
NY). TZM-bl indicator cells were infected with viral
supernatant containing 10 ng of CA. Relative infectivity
expressed as relative light units (RLU) was measured using
the Bright-Glo luciferase assay system kit (Promega)
and an ARVO MX luminescence counter (PerkinElmer,
Waltham, MA). The data represent the results of three
independent experiments.
ERT assay
The following plasmids were used: pTR600, empty vector;
WT A3H HapII expressed as an N-terminal FLAG-tagged
protein in pTR600 (pA3H WT); A3H E56A active site
mutant expressed as an N-terminal FLAG-tagged protein
in pTR600 (pA3H E56A); and pNL4-3vif (−).
Transfections were performed as described previously
[109], except that TransIT-293 from Mirus Bio LLC
(Madison, WI) was used, according to the manufac-
turer’s instructions. Briefly, 100-mm cell culture dishes
were seeded with 3 × 105 293T cells in Dulbecco’s modi-
fied Eagle’s Medium with 10% fetal bovine serum. Two
days later, the cells were transfected in duplicate with
15 μg of pNL4-3vif (−) and 0, 1.5, or 5 μg of pA3H WT
or pA3H E56A plasmid; the molar ratios of pNL4-3vif
(−) to A3H plasmid were therefore 10:1 or 3:1, respect-
ively. The pTR600 plasmid was the negative control and
was also used to generate a constant level (5 μg) of trans-
fected pTR600 DNA, with or without the A3H insert. Cul-
ture fluids were changed 24 h after transfection, then
harvested after two consecutive 24-h periods, and passed
through 0.22 μm filters. Samples from each culture were
pooled and were treated sequentially with DNase I and
subtilisin, as described [109,110].
ERT reactions were performed without Triton X-100
pretreatment and nucleic acids were isolated as detailed in
Thomas et al. [109]. Real-time PCR for the detection of
R-U5 and R-5’UTR was performed in duplicate as described
previously [111]. The kinetics of DNA synthesis were plot-
ted and the data were normalized relative to maximal
R-U5 copies at 240 min for pNL4-3vif (−) in the absence
of A3H cotransfected plasmid. Each data point was the
result of two independent transfections, each measured
in duplicate. Error bars represent the standard error of
the mean.
Additional files
Additional file 1: Figure S1. Sequence alignment of residues in the
Zn-binding (Z) domains of the seven A3 proteins (A to H). The
Zn-coordinating (H and C) and active site (E) residues are highlighted in
light blue. A3H residues that differ from highly conserved residues at the
corresponding positions in the other A3 proteins are shown in lavender.
Mitra et al. Retrovirology  (2015) 12:3 Page 13 of 15The residues in loop 7 are bracketed. The numbers at the end of each
line represent the position in the full-length protein. The percent
sequence identity of each Z domain relative to that of A3H (defined as
100%) is indicated. The sequence alignment was performed using
Lasergene software (DNASTAR, Inc., Madison, WI).
Additional file 2: Figure S2. Superposition of the structures of the
current A3H model and other A3 proteins in ribbon representation. The
backbone traces are colored gray (A3H) and green (other A3 proteins).
The Zn ions are shown in brown (A3H) and in coral (other A3 proteins).
(A) A3H and A3G-CTD. (B) A3H and A3A. (C) A3H and A3C. (D) A3H
and A3F-CTD.
Additional file 3: Figure S3. Electrostatic surface potential maps of
A3H and other A3 proteins. (A) A3H. (B) A3G-CTD. (C) A3A. (D) A3C.
(E) A3F-CTD. Regions with positive and negative electrostatic potentials
are highlighted in blue and red, respectively.
Additional file 4: Figure S4. Comparison of antiviral activities of A3H
and A3G WT and catalytic mutants. Virions produced from 293T cells
transfected with HIV-1vif(−) (1 μg) and either 0.1 (gray bars) or 1 μg
(black bars) of the indicated A3H or A3G WT or mutant plasmids.
Infectivity was assayed as described in Methods. The catalytic mutants
are E56A (A3H) and E259Q (A3G). A vector control (100% infectivity)
was also included.
Additional file 5: Table S1. Oligonucleotides used for deaminase
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